A document titled "First-line treatment for Durable Pain Control". The document is divided into two sections. The top section is titled "Designed to Deliver" and has an illustration of a shield with a lock on it. Below the shield there is text that explains that the product is designed to deliver over 12 hours only and has a true matrix for every-12-hour dosing.
The bottom section of the document has a list of no known CYP450 drug-drug interactions at clinically relevant doses. The text explains that over 12 weeks of continuous treatment increases in pain scores (VAS) with a stable dose over the entire 12-week period. There is also a note that says "With less supplemental rescue medication use than the allowable maximum in clinical trials".
At the bottom of the page there are two logos one for Opana ER and the other for Oxymorphone HCI (Extended-release HCI). The company's logo is also visible in the bottom right corner.
Description 
Type
Category
-
Date
2009
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
